Significantly, pharmacological inhibition of the spliceosome using pladienolide B and SD6 in RB1-mutant cells led to widespread intron retention, reduced cellular proliferation, and compromised tumorigenesis ability, underscoring the therapeutic potential of targeting splicing dysregulation in RB1-deficient cancers. The gene discussed is RB1; the disease is cancer.